Objective: To review the current evidence on the efficacy and safety of botulinum toxin-A in the management of idiopathic overactive bladder (OAB). Methods: A systematic search of PubMed, Embase and the Cochrane Central Search Library was performed. All randomized controlled trials comparing botulinum toxin-A with placebo, different doses and injection techniques, in patients with idiopathic OAB was included. The analyzed outcomes were quantification of symptoms, urodynamic outcomes, quality of life and adverse events. Result: A total of 1,020 participants from 12 randomized controlled trials were included. Botulinum toxin-A was associated with less urinary frequency, less incontinence episodes, improvement in quality of life, higher post-void residual-related catheterization and higher urinary tract infection. Doses of 100-300 U were not consistently differentiated from each other in voiding diary, quality of life and urge urinary incontinence. No statistically significant difference was seen between bladder body and bladder base, bladder body and bladder body plus trigone in urinary retention and urinary tract infection. Conclusion: Botulinum toxin-A is associated with significant improvement in OAB symptoms in patients with idiopathic OAB. However, there is a higher incidence of postoperative urinary retention and urinary infection compared to placebo. Low-dose botulinum toxin-A seems to be the optimum dose that appropriately balances the benefits with adverse events. Trigone inclusion seems as safe and effective as trigone-sparing injection.

Keywords:
Idiopathic overactive bladder, Botulinum toxin-A, Meta-analysis
1.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178.
2.
Asimakopoulos AD, Cerruto MA, Del Popolo G, La Martina M, Artibani W, Carone R, et al: An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity. Urol Int 2012;89:259-269.
3.
Schurch B, Schmid DM, Stohrer M: Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000;342:665.
4.
Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D: Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011;12:CD005493.
5.
Anger JT, Weinberg A, Suttorp MJ, Litwin MS, Shekelle PG: Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol 2010;183:2258-2264.
6.
Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, et al: Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012;62:507-514.
7.
Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, et al: OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol 2012;62:148-157.
8.
Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al: Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184:2416-2422.
9.
Brubaker L, Gousse A, Sand P, Thompson C, Patel V, Zhou J, et al: Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J 2012;23:1017-1025.
10.
Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P: Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 2011;30:556-562.
11.
Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, et al: Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol 2012;61:520-529.
12.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
13.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
14.
King J, Neville J: A randomized, double-blind, placebo-controlled trial of botulinum toxin type A injection for the treatment of refractory idiopathic detrusor overactivity. Int Urogynecol J 2007;18(suppl 1):S25-S105.
15.
Brubaker L, Kreder K, Richter HE, Lavelle J, Wei JT, Mahajan S, Weber AM: Refractory urge urinary incontinence and botulinum A injection: the methods of the RUBI trial. J Appl Res 2006;6:260.
16.
Sahai A, Khan MS, Dasgupta P: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007;177:2231-2236.
17.
Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TE, et al: Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 2012;61:928-935.
18.
Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al: Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-222.
19.
Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD: Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009;181:2608-2615.
20.
Sahai A, Dowson C, Khan MS, Dasgupta P: Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009;103:1509-1515.
21.
Altaweel W, Mokhtar A, Rabah DM: Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder. Urol Ann 2011;3:66-70.
22.
Cohen BL, Barboglio P, Rodriguez D, Gousse AE: Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009;28:205-208.
23.
Kuo HC: Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 2011;30:1242-1248.
24.
Kuo HC: Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol 2007;178(4 Pt 1): 1359-1363.
25.
Cerruto MA, Asimakopoulos AD, Artibani W, Del Popolo G, La Martina M, Carone R, et al: Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity. Urol Int 2012;89:1-8.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.